SensiStain™ Anti-Claudin 18.2 Antibody單株抗體   | 貨號HY500141

SensiStain™ Anti-Claudin 18.2 Antibody

Claudin 18.2 參與腫瘤的發生(tumor development)和進展，透過鈣獨立的細胞黏附活性(calcium-independent cell-adhesion activity)在細胞間隙的緊密連接特異性消除中起主要作用

Cat. No.	HY500141
Name	SensiStain™ Anti-Claudin 18.2 Antibody
Clone	IHC758
Category	IHC Antibodies
Gene Name	Claudin 18.2
Application	ELISA, IHC
Raised In	Rabbit
Clonality	Monoclonal
Reactivity	Human
Description	Claudin 18.2 is involved in tumor development and progression, has a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity, and is located in the outer cell membrane.
Immunogen	Recombinant Protein
Isotype	IgG
Recommended Dilutions	1:50-1:200
Storage Buffer	Tris Buffer, pH 7.3 – 7.7, with 1% BSA and <0.1% Sodium Azide
Storage Condition	This product is stable for several weeks at 4°C as an undiluted liquid. Dilute only prior to immediate use. For extended storage aliquot contents and freeze at -20°C or below. Avoid cycles of freezing and thawing.
Material Citation	If use of this material results in a scientific publication, please cite the material in the following manner: Applied Biological Materials Inc, Cat. No. HY500141

 His Tag單株抗體  | HA Tag 單株抗體 |  GFP Tag  單株抗體 | D Tag  單株抗體  |GST Tag  單株抗體 | Myc Tag  單株抗體 |  V5 Tag  單株抗體

研究級生物相似藥抗體(research-grade biosimilar antibodies) 

MedChemExpress (MCE) 抑制性抗體(Inhibitory Antibodies )是研究級生物相似藥抗體(research-grade biosimilar antibodies)，具有與原始治療抗體相同的生物活性成分(bioactive component)。生物相似藥( Biosimilar)使得研究藥物的生物效應成為可能。這些抗體特異性結合標靶細胞或蛋白質，刺激免疫系統攻擊惡性腫瘤細胞或阻斷特定細胞受體來阻止腫瘤生長。標靶蛋白包括CD20、HER2、EGFR、VEGFR、TNF-α等。MCE抑制抗體已廣泛應用於癌症(cancer)、免疫學(immunology )和感染(infection)等最熱門的研究領域。

MCE 抑制抗體(MCE Inhibitory Antibodies)是單株抗體 (mAb)，已廣泛應用於癌症(cancer)、免疫學( immunology )和感染(infection)等最熱門的研究領域。這些單株抗體（mAb）單一特異性地與某些細胞或蛋白質結合，從而刺激免疫系統攻擊惡性腫瘤細胞，並透過阻斷特定的細胞受體來防止腫瘤生長。它們可以抑制PD-1、PD-L1、EGFR、VEGFR、TNF-α 或其他在疾病中異常活躍的靶點，例如非何杰金氏淋巴瘤(non-Hodgkin lymphom)、A 型血友病( Hemophilia A)、腎細胞癌(renal cell carcinoma)、帕金森氏症(Parkinson’s disease)和轉移性HER2 陽性乳癌癌症(metastatic HER2-positive breast cancer)。例如，透過與 VEGF 結合，貝伐單抗(Bevacizumab )可防止 VEGF 與其受體相互作用，從而抑制新血管生長(inhibiting new vessel growth)。蘭博利珠單抗(Lambrolizumab)靶向淋巴細胞的程序性細胞死亡 1 (PD-1) 受體。透過阻止其配體（PD-L1 和 PD-L2）的結合，Lambrolizumab 誘導抗腫瘤免疫反應。

Zolbetuximab (IMAB362)  | CAS#1496553-00-4 MCE貨號HY-P99058  96.98%

(Synonyms: IMAB362)